Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of AB-106 with Itraconazole and Rifampicin in Healthy Men
NCT05357820Phase 1Completed
- Sponsor
- Nuvation Bio
- Start
- Jul 2021
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of taletrectinib in solid tumor and non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Nuvation Bio. Primary endpoint: AB-106 PK Exposure Parameters at 29 days. Started Jul 2021; status: completed.
02
Drugs
taletrectinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05357820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357820.